The potential diagnostic accuracy of circulating microRNAs for Alzheimer's disease : A meta-analysis
Copyright © 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved..
BACKGROUND & OBJECTIVE: Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease that seriously affects cognitive ability and has become a key public health problem. Many studies have identified the possibility of peripheral blood microRNA as effective non-invasive biomarkers for AD diagnosis, but the results are inconsistent. Therefore, we carried out this meta-analysis to evaluate the diagnostic accuracy of circulating microRNAs in the diagnosis of AD patients.
METHODS: We performed a systematic literature search of the following databases: PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang database and China National Knowledge Infrastructure, updated to March 15, 2021. A random effects model was used to pool the sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the curve. Meta-regression and subgroup analysis were performed to explore the sources of heterogeneity, and Deeks' funnel plot was used to assess whether there was publication bias.
RESULTS: 62 studies from 18 articles were included in this meta-analysis. The pooled sensitivity was 0.82 (95% CI: 0.78-0.85), specificity was 0.80 (95% CI: 0.76-0.83), PLR was 4. 1 (95% CI: 3.4-4.9), NLR was 0.23 (95% CI: 0.19-0.28), DOR was 18 (95% CI: 13-25) and AUC was 0.88 (95% CI: 0.84-0.90). Subgroup analysis shows that the microRNA clusters of plasma type performed a better diagnostic accuracy of AD patients. In addition, publication bias was not found.
CONCLUSIONS: Circulating microRNAs can be used as a promising non-invasive biomarker in AD diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Neurologia - 39(2024), 2 vom: 20. März, Seite 147-159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, W T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer's disease |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 16.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nrleng.2023.12.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369507266 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369507266 | ||
| 003 | DE-627 | ||
| 005 | 20240417232614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nrleng.2023.12.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM369507266 | ||
| 035 | |a (NLM)38460993 | ||
| 035 | |a (PII)S2173-5808(23)00079-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, W T |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The potential diagnostic accuracy of circulating microRNAs for Alzheimer's disease |b A meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND & OBJECTIVE: Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease that seriously affects cognitive ability and has become a key public health problem. Many studies have identified the possibility of peripheral blood microRNA as effective non-invasive biomarkers for AD diagnosis, but the results are inconsistent. Therefore, we carried out this meta-analysis to evaluate the diagnostic accuracy of circulating microRNAs in the diagnosis of AD patients | ||
| 520 | |a METHODS: We performed a systematic literature search of the following databases: PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang database and China National Knowledge Infrastructure, updated to March 15, 2021. A random effects model was used to pool the sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the curve. Meta-regression and subgroup analysis were performed to explore the sources of heterogeneity, and Deeks' funnel plot was used to assess whether there was publication bias | ||
| 520 | |a RESULTS: 62 studies from 18 articles were included in this meta-analysis. The pooled sensitivity was 0.82 (95% CI: 0.78-0.85), specificity was 0.80 (95% CI: 0.76-0.83), PLR was 4. 1 (95% CI: 3.4-4.9), NLR was 0.23 (95% CI: 0.19-0.28), DOR was 18 (95% CI: 13-25) and AUC was 0.88 (95% CI: 0.84-0.90). Subgroup analysis shows that the microRNA clusters of plasma type performed a better diagnostic accuracy of AD patients. In addition, publication bias was not found | ||
| 520 | |a CONCLUSIONS: Circulating microRNAs can be used as a promising non-invasive biomarker in AD diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Alzheimer's disease | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Diagnóstico | |
| 650 | 4 | |a Enfermedad de Alzheimer | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Metaanálisis | |
| 650 | 4 | |a MicroARN | |
| 650 | 4 | |a MicroRNA | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Circulating MicroRNA |2 NLM | |
| 700 | 1 | |a Zhang, G X |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, S S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurologia |d 2007 |g 39(2024), 2 vom: 20. März, Seite 147-159 |w (DE-627)NLM171204786 |x 2173-5808 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g number:2 |g day:20 |g month:03 |g pages:147-159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nrleng.2023.12.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |e 2 |b 20 |c 03 |h 147-159 | ||